. "331731-18-1"@en . . . "10-20 days."@en . "Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement."@en . . . " "@en . . . . . . . . . . . . . "Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons."@en . . "approved"@en . "* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]"@en . . "# PDB sequence \"Link\":http://www.rcsb.org/pdb/download/downloadFile.do?fileFormat=FASTA&compression=NO&structureId=1IGT # Patent Information \"Link\":http://www.freepatentsonline.com/6090382.html"@en . . . . "Adalimumab"@en . . . "For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease."@en . . . . . . "Humans and other mammals"@en . . . "Ig gamma-1 chain C region"@en .